Table 1.
Maternal Baseline Characteristics by Study Treatment Duration
| Characteristic | Total (N = 422) | 7-Day Arm (n = 219) | 21-Day Arm (n = 203) | |
|---|---|---|---|---|
| Age at sdNVP dosing, y | Median (10%, 90%) | 26 (21, 34) | 26 (20, 35) | 25 (21,33) |
| Gestational age at sdNVP dosing, wk | Median (10%, 90%) | 38 (36, 41) | 38 (36, 41) | 38 (35, 41) |
| Race/ethnicity | Asian (other than Indian) | 1 (0%) | 1 (0%) | 0 (0%) |
| Black African | 260 (62%) | 137 (63%) | 123 (61%) | |
| Black of African origin | 58 (14%) | 31 (14%) | 27 (13%) | |
| Indian (Native of India) | 103 (24%) | 50 (23%) | 53 (26%) | |
| HIV-1 RNA, log10 copies/mL | Median (10%, 90%) | 3.50 (2.60, 4.83) | 3.51 (2.55, 4.81) | 3.50 (2.60, 4.85) |
| Mean (SD) | 3.56 (0.90) | 3.56 (0.91) | 3.57(0.90) | |
| HIV-1 RNA, copies/mL | ≤400 | 83 (20%) | 42 (19%) | 41 (20%) |
| 401–999 | 48 (11%) | 25 (11%) | 23 (11%) | |
| 1000–9999 | 148 (35%) | 79 (36%) | 69 (34%) | |
| 10 000–99 999 | 112 (27%) | 55 (25%) | 57 (28%) | |
| ≥100 000 | 29 (7%) | 17 (7%) | 12 (6%) | |
| Missing | 2 | 1 | 1 | |
| Screening CD4 count, cells/mm3 | Median (10%, 90%) | 490 (320, 861) | 468 (305, 777) | 508 (338, 888) |
| 250–349 | 69 (16%) | 43 (20%) | 26 (13%) | |
| 350–499 | 150 (36%) | 78 (36%) | 72 (35%) | |
| ≥500 | 203 (48%) | 98 (45%) | 105 (52%) | |
| Actual ZDV exposure during pregnancy | Yes | 267 (63%) | 136 (62%) | 131 (65%) |
| No | 155 (37%) | 83 (38%) | 72 (35%) | |
| HIV-1 subtype | A1 | 56 (15%) | 27 (13%) | 29 (16%) |
| A2 | 1 (0%) | 1 (0%) | 0 (0%) | |
| B | 54 (14%) | 29 (14%) | 25 (14%) | |
| C | 237 (62%) | 126 (62%) | 111 (62%) | |
| D | 32 (8%) | 19 (9%) | 13 (7%) | |
| Complex recombinant | 2 (1%) | 1 (0%) | 1 (1%) | |
| Unclassified | 1 (0%) | 0 (0%) | 1 (1%) | |
| Unknown | 39 | 16 | 23 |
Abbreviations: HIV-1, human immunodeficiency virus type 1; sdNVP, single-dose nevirapine; ZDV, zidovudine.